SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?


To: If only I'd held who wrote (30129)4/14/1999 1:54:00 PM
From: ACS_101  Read Replies (2) | Respond to of 122087
 
IMCL -- Reports that their C225 compound, already in Ph III trials for certain kinds of neck tumors, showed positive in pre-clinical trials against a mouse model of pancreatic cancer in combination with another anti-cancer drug.

I know mice are mice, but I believe pancreatic cancer has been one of the most dreaded and untreatable forms of this disease....maybe suggests C225 has much broader efficacy.